Evidence map›Paper›PMID 41865063›Full record

ArticleCell death discovery2026

Sublethal DNA damage switches off B cell effector programs in an RA-FLS-PBMC co-culture.

Denada Bruci, Torsten Lowin, Gerhard Fritz, Georg Pongratz

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Denada BruciDepartment of Rheumatology and Hiller Research Center, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. denada.bruci@med.uni-duesseldorf.de.ORCID http://orcid.org/0009-0007-2665-0828
Torsten LowinDepartment of Rheumatology and Hiller Research Center, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.ORCID http://orcid.org/0000-0001-7368-2776
Gerhard FritzInstitute of Toxicology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Georg PongratzDepartment of Rheumatology, Barmherzige Brüder Hospital, Regensburg, Germany.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 417677437/GRK2578
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) features lymphocyte-driven inflammation, in which B cells, alongside T cells, play key effector roles (e.g., autoantibody production, antigen presentation, cytokine or chemokine production). Within activated B cells, during normal diversification, activation-induced cytidine deaminase (AID) introduces targeted DNA lesions in immunoglobulin loci (class-switch recombination/somatic hypermutation), creating a potential vulnerability to sublethal genotoxic stress. T cells also contribute to RA pathogenesis through cytokine production and cell-mediated responses, and are exposed to similar genotoxic stressors in the inflamed joint environment. Given this, we asked whether a single dose/concentration of sublethal genomic damage can modulate lymphocyte effector function without overt cytotoxicity. Peripheral blood mononuclear cells from healthy donors were co-cultured with RA fibroblast-like synoviocytes and exposed once to an IC₂₀ or IC₅₀ dose/concentration of γ-irradiation (γ-IR), hydrogen peroxide (H₂O₂), or the oxazaphosphorine metabolite 4-hydroperoxyifosfamide (4-OOH IFA). Viability, γ-H2AX kinetics, cell cycle status, cytokine and immunoglobulin secretion, and a 28-gene damage response/differentiation panel were quantified at either 24 hours or 5 days post-treatment. Together, the data indicate that a single, carefully titrated low-concentration genotoxic hit might selectively suppress lymphocyte effector programs, with B cells being more durably affected than T cells. At 2 Gy, overall cell viability remained above 80%, whereas IL-10 expression declined by approximately 70%, indicating functional silencing in the absence of substantial cytotoxicity. Conceptually, targeting this vulnerability might help to dampen B cell activity in RA while largely preserving overall immune viability and T cell competence.

Identifiers

PMID41865063
PMCPMC13039513

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.